Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19635976 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL10698128 | 0.80 | HTR2C (0.43) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL5491000 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL16903465 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL2502213 | 0.76 | HTR2C (0.46) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL2146179 | 0.76 | HTR2C (0.46) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL18340933 | 0.76 | HTR2C (0.46) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL16903468 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL17956483 | 0.73 | USP30 (0.38) | — | |
| SCHEMBL2202910 | 0.72 | DDB1 (0.44) | SMN1; SMN2NPC1RAB9AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981984-B2 | Method for producing cis-5-hydroxy-2-piperidinecarboxylic acid derivative, and method for purifying cis-5-hydroxy-2-piperidinecarboxylic acid | API CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20150239906-A1 | Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid | UBE CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239906-A1 | Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid | HCAR2, HCAR1, C5 | SMN1; SMN2 3680/4885NPC1 3080/4885RAB9A 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.